Physician profile
Amit Kumar Masih
NPI 1124219175
$784,679.32
in general payments reported to CMS, 2019-2025
46 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174K · 2020: $142K · 2021: $136K · 2022: $101K · 2023: $81K · 2024: $57K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $126K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Consulting Fee: $21K · Travel and Lodging: $12K · Food and Beverage: $9,977 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $125,974.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,062.50 |
| Consulting Fee | $20,890.27 |
| Travel and Lodging | $12,433.86 |
| Food and Beverage | $9,977.49 |
| Education | $311.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $187,811.59 | 2020-2025 | Vyepti, Rexulti |
| Amgen INC. | $151,795.81 | 2019-2023 | Aimovig |
| Abbvie INC. | $129,289.14 | 2021-2025 | |
| Lilly USA, LLC | $121,357.17 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $98,300.72 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Allergan, INC. | $66,433.72 | 2019-2022 | |
| Axsome Therapeutics, INC. | $19,600.04 | 2025 | Symbravo, Sunosi |
| Biohaven Pharmaceuticals, INC. | $6,800.06 | 2021 | |
| Pfizer INC. | $433.65 | 2023-2025 | |
| Ucb, INC. | $317.18 | 2023-2025 | Nayzilam, Briviact, Fintepla |
| Sk Life Science, INC. | $282.94 | 2022-2025 | Xcopri |
| Eisai INC. | $235.55 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.91 | 2022-2025 | Hyqvia |
| Genzyme Corporation | $174.90 | 2022 | |
| Biogen, INC. | $151.79 | 2022-2025 | Spinraza, Qalsody, Tysabri |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $134.89 | 2023-2024 | Aptiom |
| Scilex Pharmaceuticals INC. | $125.75 | 2023-2024 | Ztlido |
| Novartis Pharmaceuticals Corporation | $110.42 | 2019 | |
| Genentech USA, INC. | $109.81 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Averitas Pharma INC. | $104.87 | 2023-2025 | Qutenza |
| Argenx US, INC. | $80.97 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $73.84 | 2023-2025 | Rexulti, Nuedexta |
| Csl Behring | $72.96 | 2023-2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $65.52 | 2019-2023 | Ultomiris |
| Neurelis, INC. | $56.32 | 2024-2025 | Valtoco |
| Tanabe Pharma America, INC. | $51.96 | 2023-2024 | |
| Kyowa Kirin, INC. | $46.14 | 2023-2024 | Nourianz |
| Xeris Pharmaceuticals, INC. | $40.41 | 2023-2024 | Keveyis |
| Grt US Holding, INC. | $39.73 | 2021 | |
| Jazz Pharmaceuticals INC. | $36.11 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.89 | 2022 | |
| Impel Pharmaceuticals INC. | $34.54 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $30.73 | 2022-2023 | Onpattro |
| Vanda Pharmaceuticals INC. | $27.23 | 2025 | Ponvory |
| Octapharma USA, INC. | $26.54 | 2024 | Panzyga |
| Catalyst Pharmaceuticals, INC. | $25.40 | 2024 | |
| Amneal Pharmaceuticals LLC | $23.27 | 2025 | Crexont |
| Emd Serono, INC. | $18.95 | 2019 | |
| Kedrion Biopharma, INC. | $18.81 | 2024 | Kedrab, Gammaked, Koate |
| Sage Therapeutics, LLC | $17.87 | 2023 | |
| Genentech, INC. | $17.60 | 2023 | Evrysdi |
| Acorda Therapeutics, INC | $17.23 | 2023 | Inbrija |
| Neurocrine Biosciences, INC. | $16.32 | 2020 | |
| Corium, LLC | $15.90 | 2023 | Adlarity |
| Sarepta Therapeutics, INC. | $14.17 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Masih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.